A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

Trial Profile

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs Nazartinib (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 19 Oct 2017 Planned End Date changed from 25 Jul 2019 to 20 Sep 2019.
    • 15 Jun 2017 Planned primary completion date changed from 25 Jul 2019 to 11 Feb 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top